[HTML][HTML] Cyclophosphamide arrhythmogenicitytesting using human-induced pluripotent stem cell-derived cardiomyocytes
AD Podgurskaya, MM Slotvitsky, VA Tsvelaya… - Scientific reports, 2021 - nature.com
Cyclophosphamide (CP) is an anticancer drug, an alkylating agent. Cardiotoxicity of CP is
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …
Cyclophosphamide arrhythmogenicitytesting using human-induced pluripotent stem cell-derived cardiomyocytes
AD Podgurskaya, MM Slotvitsky… - Scientific …, 2021 - ui.adsabs.harvard.edu
Cyclophosphamide (CP) is an anticancer drug, an alkylating agent. Cardiotoxicity of CP is
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …
Cyclophosphamide arrhythmogenicitytesting using human-induced pluripotent stem cell-derived cardiomyocytes
AD Podgurskaya, MM Slotvitsky… - Scientific …, 2021 - pubmed.ncbi.nlm.nih.gov
Cyclophosphamide (CP) is an anticancer drug, an alkylating agent. Cardiotoxicity of CP is
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …
[HTML][HTML] Cyclophosphamide arrhythmogenicitytesting using human-induced pluripotent stem cell-derived cardiomyocytes
AD Podgurskaya, MM Slotvitsky, VA Tsvelaya… - Scientific …, 2021 - ncbi.nlm.nih.gov
Cyclophosphamide (CP) is an anticancer drug, an alkylating agent. Cardiotoxicity of CP is
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …
[引用][C] Cyclophosphamide arrhythmogenicitytesting using human-induced pluripotent stem cell-derived cardiomyocytes
AD Podgurskaya, MM Slotvitsky, VA Tsvelaya… - Scientific Reports, 2021 - elibrary.ru
We thank Suren Zakian's lab for providing the hiPSCs of a healthy donor and Nina
Kudryashova for useful discussion. This work was supported by grant № 19-315-90113 from …
Kudryashova for useful discussion. This work was supported by grant № 19-315-90113 from …
Cyclophosphamide arrhythmogenicitytesting using human-induced pluripotent stem cell-derived cardiomyocytes.
AD Podgurskaya, MM Slotvitsky, VA Tsvelaya… - Scientific …, 2021 - europepmc.org
Cyclophosphamide (CP) is an anticancer drug, an alkylating agent. Cardiotoxicity of CP is
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …
Cyclophosphamide arrhythmogenicitytesting using human-induced pluripotent stem cell-derived cardiomyocytes.
AD Podgurskaya, MM Slotvitsky… - Scientific …, 2021 - search.ebscohost.com
Cyclophosphamide (CP) is an anticancer drug, an alkylating agent. Cardiotoxicity of CP is
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …